Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.42% on an annualized basis producing an average annual return of 16.4%. Currently, AbbVie has a market capitalization of $263.04 billion.

You no longer need surgery to be diagnosed with endometriosis. Here's what's changed

You no longer need surgery to be diagnosed with endometriosis. Here's what's changed

By age 44, endometriosis affects around one in nine women and people assigned female at birth in Australia.

The Conversation

AbbVie Whale Trades For June 01

AbbVie Whale Trades For June 01

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Supreme Court leak prompts investors to press companies on abortion

WASHINGTON — Activist shareholders, seeking to galvanize support following a leaked Supreme Court draft opinion indicating that justices are poised to overturn Roe v. Wade, are pressing companies to explicitly explain how they will support their workers’ access to abortion and reproductive health services.

Tribune News Service

SCOTUS leak prompts investors to press companies on abortion - Roll Call

Activist shareholders are pressuring companies on access to abortion after a leaked draft Supreme Court opinion.

If You Invested $1000 In AbbVie 5 Years Ago, Here's How Much You Would Have Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 7.1% on an annualized basis producing an average annual return of 17.45%. Currently, AbbVie has a market capitalization of $260.97 billion.

What 8 Analyst Ratings Have To Say About AbbVie

Within the last quarter, AbbVie (NYSE:ABBV) has observed the following analyst ratings:

inkl

Read news from The Economist, FT, and more,
with one subscription

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy. AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

Five Leading Stocks That At Least Double The S&P 500's Yield

Five Leading Stocks That At Least Double The S&P 500's Yield

Low-risk dividend stocks are coveted. Better yet, here are quality CAN-SLIM stocks that pay at least double the S&P 500 index's yield.

Investors Business Daily

AbbVie Whale Trades Spotted

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate

AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate

AbbVie Inc (ABBV) and Cugene Inc have announced an exclusive worldwide license option agreement for CUG252 for the potential treatment of autoimmune and inflammatory diseases. Cugene's lead candidate, CUG252, is an engineered IL-2 mutein designed to selectively activate and expand immune-suppressive Treg cells while reducing undesired IL-2 activity on other IL-2 receptor-expressing cells for autoimmune…

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Investors Business Daily

AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year

AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year

AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease. The trial included patients who had an inadequate response or were intolerant to conventional or biologic therapy. A significantly higher proportion of patients who received upadacitinib 15 mg or 30…

Top Funds Bet On These Stocks To Rise From Down Market

Top Funds Bet On These Stocks To Rise From Down Market

Led with a more-than $3 billion bet on Apple, the best mutual funds continue to invest heavily during this market correction.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stocks That Lift This JPMorgan Fund In Down Market

Most mutual funds have losses this year amid the market's sell-off. But JPMorgan Large Cap Value Fund is in positive territory. Here's why.

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

U.S. FDA Approves AbbVie's RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .

Investors Business Daily

Stock Market Down More Than 2%, Wiping Out Most Of Thursday's Rally; Amazon Hits Indexes

The stock market sank to session lows in afternoon trading Friday as index losses topped 2%. The S&P 500 plunged 2.1% and undercut Thursday's lows, essentially wiping out almost all of that day's 2.5% rally. The Nasdaq composite slid 2.4%, though it is holding above Thursday's low. The Dow Jones…

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review

A market rally attempt is underway, but the major indexes lost ground. Apple and Facebook led key earnings. Elon Musk will buy Twitter.

Investors Business Daily

Stock Market Drops On Lackluster Earnings From Amazon, Apple

The stock market dropped Friday after Amazon, Apple and others reported lackluster earnings and guidance.

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades.

AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Investors Business Daily

AbbVie Crumbles On Mixed Earnings, Slashes 2022 Profit Outlook

AbbVie beat first-quarter earnings forecasts, though sales came in light and the firm cut its 2022 profit guide. AbbVie stock fell Friday.

AbbVie: Q1 Earnings Insights

AbbVie (NYSE:ABBV) reported its Q1 earnings results on Friday, April 29, 2022 at 07:44 AM. Here's what investors need to know about the announcement.

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.18% on an annualized basis producing an average annual return of 18.59%. Currently, AbbVie has a market capitalization of $275.98 billion.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

277,807 stories

Washington D.C.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play